This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: guidelines

Familial hypercholesterolaemia –  a developing English scandal

April 2011 Br J Cardiol 2011;18:54−5

Familial hypercholesterolaemia – a developing English scandal

Jonathan Morrell

Abstract

Findings Nearly 70% of eligible PCTs responded to this survey, with many PCTs admitting to a lack of formal planning for FH, and incomplete knowledge about relevant FH services. Looking at the results as a whole, I think it is safe to say that the failure to implement the guidelines at PCT level suggests that national guidance is not always given local priority. More than 40% of the respondents admitted to a shortage of specialist care for people with FH, including adults, children and pregnant women. A number of PCTs indicated that they face barriers to treating FH patients and these concerns need to be addressed immediately if the guidelin

| Full text
Should the BSE collaborate with the BSG on intravenous sedation?

May 2010 Br J Cardiol 2010;17:103

Should the BSE collaborate with the BSG on intravenous sedation?

Terry McCormack

Abstract

Gastroenterology guidelines The British Society of Gastroenterology (BSG) guidelines suggest that the opiate is used before the benzodiazepine.3 The BSG guidelines also suggest a maximum dose of 5 mg midazolam and 50 mg pethidine. Mankia et al. seem to permit 10 mg midazolam and 75 mg pethidine in their proposed protocol. Such doses would seem excessive unless you have confidence in your ability to provide assisted ventilation. In the survey nobody appears to have used more than 50 mg pethidine and, therefore, practitioners appear to set their own sensible cut-off points. In gastroscopy, sedation is often avoided, however, the TEE is of a mu

| Full text

March 2010 Br J Cardiol 2010;17:59-61

New NICE guidance on VTE prevention

BJ Cardio Staff

Abstract

NICE calculates that an estimated 25,000 people who are admitted to hospital die from preventable VTE each year.  The NICE guideline, jointly developed with the National Clinical Guideline Centre for Acute and Chronic Conditions, recommends that all patients should be assessed for risk of developing blood clots on admission to hospital, and then given preventative treatment that suits their individual needs. Options include anticoagulant drugs such as heparin, anti-embolism stockings and foot impulse or pneumatic devices.  This advice covers all patients admitted to hospital – including those having day-case procedures – and not just th

| Full text
NICE preliminary hearing negative on new antiarrhythmic 

March 2010 Br J Cardiol 2010;17:59-61

NICE preliminary hearing negative on new antiarrhythmic 

BJ Cardio Staff

Abstract

But UK cardiologists and arrhythmia patient/professional groups, led by the Atrial Fibrillation Association and Heart Rhythm UK, have been petitioning to have this draft recommendation overturned. A second NICE meeting on dronedarone was held at the end of February to consider all the comments that have been received, and a final guidance is expected in the next few weeks. As part of the campaign to allow dronedarone to be available for NHS prescription, more than 100 doctors have signed an open letter to NICE setting out reasons why the drug is needed. A Parliamentary Stakeholder Investigation on the issue has been held and a Parliament Earl

| Full text

July 2009 Br J Cardiol 2009;16:187–91

Follow your heart: optimal care after a heart attack – a guide for you and your patients

Fran Sivers, Alan Begg, David Milne, Jonathan Morrell, Dermot Neely, Michael Norton, Michaela Nuttall, Malcolm Walker, Brian Ellis, Cathy Ratcliffe, Andrew Thomas, Ruth Bosworth, Seleen Ong, on behalf of the Follow Your Heart Steering Group

Abstract

Introduction Coronary heart disease (CHD) remains the leading cause of mortality in the UK with over 94,000 attributable deaths in 2006,1 the majority of which were the result of a myocardial infarction (MI). Approximately half of those who suffer an MI die within 28 days,2 however, with modern technology, procedures and new drugs, increasing numbers survive a heart attack, resulting in 1.4 million post-MI survivors in the UK.3 If patients do not receive optimal post-MI care, the individual and socio-economic burden is significant. In monetary terms this is estimated to be around £9 billion per year when both direct and indirect costs are in

| Full text

May 2009 Br J Cardiol 2009;16:142–6

Post-MI clinical guidelines: variation in availability, development, content and implementation across the UK

Seleen Ong, David Milne, Jonathan Morrell, on behalf of the Follow Your Heart Steering Committee

Abstract

Introduction Clinical guidelines are becoming an increasingly important component of clinical practice across Europe as governments, while facing spiralling healthcare costs, still have to maintain an overriding commitment to their citizens to provide best possible medical care. As systematically developed statements that incorporate research evidence and expert consensus views, clinical guidelines represent a means of assisting practitioners and patients on decisions about appropriate healthcare for specific circumstances.1 Adherence to clinical guidelines, thus, will help to reduce practice variation, raise standards of care, improve effici

| Full text

November 2008 Br J Cardiol 2008;15:279-80

Antibiotic prophylaxis against infective endocarditis: new guidelines, new controversy?

Richard G Bogle, Abhay Bajpai

Abstract

NICE guidance The NICE review tried to determine which cardiac conditions are associated with increased risk of IE; whether dental treatment is associated with acute risk of developing the condition and whether ABP was effective in prevention of cases and deaths. The NICE guideline concluded that patients with structural heart disease were at increased risk of IE but did not find convincing evidence that dental ABP was cost-effective. They calculated that if amoxicillin prophylaxis was effective then the cost of preventing a single case of IE would be circa £12 million. In the absence of high-quality evidence for clinical effectiveness the

| Full text

May 2007 Br J Cardiol 2007;14:125-126

The new SIGN guidance on CHD and its implications for secondary care

Kevin Jennings, Lewis Ritchie

Abstract

No content available

| Full text

March 2007 Br J Cardiol 2007;14:66-67

The new SIGN guidance on CHD and its implications for primary care

Alan G Begg

Abstract

No content available

| Full text

January 2007 Br J Cardiol 2007;14:23-8

Management of atrial fibrillation: an overview of the NICE guidance on AF management

Timothy Watson, Eduard Shanstila, Gregory Yh Lip

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now